Vanguard Capital Management
CCEL icon

Vanguard Capital Management’s Cryo-Cell International CCEL Stock Holding History

Vanguard Capital Management’s Portfolio CCEL Stock Details CCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$526K Buy
164,976
+3,452
+2% +$12.3K ﹤0.01% 3706
2026
Q1 		$573K Buy
+161,524
New +$538K ﹤0.01% 3647

Other funds holding CCEL

SA
SFI Advisors Montclair, New Jersey $116M AUM 37.12% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's CCEL Position: Q2 2026 in Review

Vanguard Capital Management increased its Cryo-Cell International (CCEL) stake by 2.1% in Q2 2026, buying an estimated $12.3K and bringing the position to 164,976 shares worth $526K. The position accounts for ﹤0.01% of the portfolio, ranked #3706.

Vanguard Capital Management first reported a position in CCEL in Q1 2026 and has held it in 2 quarters since. The position peaked at $573K in Q1 2026. 12 funds tracked by Wall St. Rank hold CCEL as of Q2 2026.

  • Vanguard Capital Management held 164,976 shares of Cryo-Cell International worth $526K as of Q2 2026.
  • Vanguard Capital Management bought 3,452 Cryo-Cell International shares in Q2 2026, an estimated $12.3K.
  • Cryo-Cell International made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3706 holding.
  • Vanguard Capital Management first reported a position in Cryo-Cell International in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Cryo-Cell International position peaked at $573K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held Cryo-Cell International as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.